L2 Diagnostics, LLC

NEW HAVEN, CT 06530
15 Employees

SBIR Award Summary

Total Number of Awards 85
Total Value of Awards $30.1MM
Active Awards 3 valued at $1.38MM
First Award Date 07/01/99
Most Recent Award Date 09/15/17

3 Active Awards Valued at $1.38MM

Award Title Awarding Agency Phase Award amount Start Date End Date
Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy HHS 1 $300K 09/15/17 08/31/18
Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy HHS 2 $781K 09/01/17 08/31/18
Validation of a Diagnostic Test for Borrelia miyamotoi HHS 1 $300K 08/14/17 07/31/18

Key Personnel

Last Name Name Awards Contact
Ledizet Michel Ledizet 23 Message
Koski Raymond A Koski 12
Kazmierczak Barbara I Kazmierczak 4
Mamula Mark J. Mamula 8
Cappello Michael Cappello 2
Rivkees Scott A. Rivkees 1
Modis Yorgo Modis 1
Anthony Karen G. Anthony 9
Wisnewski Adam Wisnewski 6
Herold Kevan C Herold 4
Peterson-Roth Elizabeth Peterson-Roth 2
Narasimhan Sukanya Narasimhan 3
Mcmahon Pratt Diane Mcmahon 2
Mootien Saraspadee Mootien 2
Bonafe Nathalie Marie Bonafe 1
Bockenstedt Linda K Bockenstedt 1
SUTHERLAND ALAN SUTHERLAND 1
KO ALBERT ICKSANG KO 2
PAL UTPAL PAL 2
USMANI-BROWN SAHAR USMANI-BROWN 3
PETERSON ROTH ELIZABETH PETERSON 1
WAJAPEYEE NARENDRA WAJAPEYEE 1
CIRILLO PIER CIRILLO 3

85 Awards Won

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/15/17 - 08/31/18

Checkpoint inhibitor (CPI) therapy has transformed treatment of solid tumors. Clinical responses in the range of 20-25%, with prolonged survival, have been reported for tumors, such as malignant melanoma and non- small cell lung cancer, that previously had poor response rates and dismal prognoses. Current therapies block PD-1/PD-L1 and CTLA-4, a...

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/01/17 - 08/31/18

Abstract The long-term product goal of this project is a small molecule rheumatoid arthritis (RA) therapeutic which acts by reducing the inflammatory response triggered by the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF). The therapeutic benefit of MIF inhibition in RA disease models has been well established by small m...

Phase 1 STTR Active

Agency: Department of Health & Human Services
Topic: PA-16-303
Budget: 08/14/17 - 07/31/18

ABSTRACT Borrelia miyamotoi is a tick-transmitted spirochete recently shown to cause infection and disease in the United States, Europe and Asia. A member of the relapsing fever group of Borrelia, this pathogen has been proven to cause most commonly a nonspecific, flu-like illness with fever, fatigue, myalgia, and headache. Disease can be partic...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 02/01/17 - 01/31/18

ABSTRACT Zika virus (ZIKV) has rapidly emerged and spread through South and Central America, the Caribbean, and Puerto Rico since its last outbreak in Micronesia in 2007. Transmitted by the mosquito Aedes sp, its forecasted spread will have a major impact on the Southeast U.S. Most ZIKV infections remain asymptomatic or present with non-specific...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/19/16 - 08/31/17

Abstract The long-term product goal of this project is a small molecule rheumatoid arthritis (RA) therapeutic which acts by reducing the inflammatory response triggered by the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF). The therapeutic benefit of MIF inhibition in RA disease models has been well established by small m...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/19/16 - 08/31/17

Abstract The long-term product goal of this project is a small molecule rheumatoid arthritis (RA) therapeutic which acts by reducing the inflammatory response triggered by the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF). The therapeutic benefit of MIF inhibition in RA disease models has been well established by small m...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 07/15/16 - 06/30/17

? DESCRIPTION (provided by applicant): The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa. This pathway is crucial to the pathogenesis of P. aeruginosa in vivo, but has not yet been exploited for antimicrobial drug discovery. There is a clear need for new tre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/16 - 06/30/17

DESCRIPTION (provided by applicant): Lyme disease (LD) caused by the Ixodes tick-borne spirochete Borrelia burgdorferi (Bb), is the most common vector-borne disease in the United States. Despite public health preventive measures, the annual confirmed case incidence has risen to over 30,000, the vast majority of which occur in the Northeast. Diss...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 03/01/16 - 02/28/17

? DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the most prevalent cancer in human population and will lead to over 23,000 deaths in the United States this year alone. However, the molecular mechanisms driving hepatocellular carcinoma (HCC) growth and metastasis remain elusive, and there is a huge, unmet medical need ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/22/15 - 06/21/16

The overall objective of this project is to identify novel biomarkers of radio-sensitivity that will identify subsets of prostate cancer patients for which radiotherapy should be contraindicated. These novel biomarkers will subsequently be packaged in a robust, validated, sensitive and specific single nucleotide polymorphism (SNP)-based assay p...

Load More